Market Overview

DJO Global Announces Financial Results for Second Quarter 2018

Share:

Strength of Business Transformation Efforts Continue to Drive
Revenue, Profit Growth

DJO Global, Inc. ("DJO" or the "Company"), a leading global provider of
medical technologies designed to get and keep people moving, today
announced financial results for its public reporting subsidiary, DJO
Finance LLC ("DJOFL"), for the second quarter ended June 30, 2018.

On January 1, 2018, DJO adopted Accounting Standards Update 2014-09,
Revenue From Contracts with Customers, (ASC 606). As a result of the
adoption, in the second quarter the Company reclassified $5.4 million of
year-to-date costs from selling, general and administrative costs to net
sales. The table below summarizes net sales and growth rates with, and
without, the adoption of ASC 606.

                             
$000's

Q2 2018 Net Sales Overview

Including ASC 606 Adoption       Excluding ASC 606 Adoption Currency Constant
Revenue       Growth Revenue Growth Impact Currency
Surgical $ 53,918 7.9 % $ 53,918 7.9 % 0.0 % 7.9 %
International 86,953 9.3 % 86,953 9.3 % 5.8 % 3.5 %
Recovery Sciences 37,454 -3.4 % 37,454 -3.4 % 0.0 % -3.4 %
Bracing and Vascular   126,512 0.1 %   131,942 4.4 % 0.0 % 4.4 %
Total DJO Global $ 304,837 3.4 % $ 310,267 5.3 % 1.6 % 3.7 %
 

Second Quarter Highlights

  • Net sales grew 5.3% to $310.3 million, or $304.8 million as reported
    with the adoption of ASC 606, compared to $294.7 million in the prior
    year period.
  • Operating income increased 296% to $35.8 million from $9.0 million in
    the prior year period.
  • Net loss attributable to DJOFL was $13.7 million, compared to a net
    loss of $34.4 million in the prior year period.
  • Adjusted EBITDA continued to expand, increasing 19.0% over the prior
    year quarter to $75.6 million.

Business Transformation

  • The previously announced business transformation continues to drive
    profitability, pushing Adjusted EBITDA margins up 280 basis points
    (excluding the impact of ASC 606 adoption) in the second quarter of
    2018 compared to the prior year, and remains on track to deliver 7% to
    10% annual cost reductions by end of 2018.
  • Including $24.8 million in future annual run-rate savings from
    transformation actions taken to date, Adjusted EBITDA for the twelve
    months ended June 30 was $312.6 million.

"We executed well in the second quarter, continuing to deliver
sustainable value from our transformation efforts, accelerating new
product introductions and overcoming market headwinds on elective
procedures," said Brady Shirley, DJO's President and Chief Executive
Officer. "I am encouraged by the momentum in our revenue growth and
expanding margins, and continue to anticipate a stronger trajectory for
the balance of our fiscal year."

Mike Eklund, Chief Financial Officer and Chief Operating Officer of DJO,
added, "We continue to work aggressively toward our profitability goals
and are realizing the benefits, with Adjusted EBITDA for the quarter
increasing 19%, or 3.6 times the growth in revenue, and margins
improving about 280 basis points. Our team has worked hard on our
transformation initiatives to improve operational efficiency, service
levels and customer experience. This quarter's financial metrics are
continued indicators of our success."

Sales Results

Net sales for DJOFL for the second quarter
of 2018 were $310.3 million, an increase of 5.3% from the prior year
period, or $304.8 million with the adoption of ASC 606. On a constant
currency basis, sales increased 3.7%. For the six months ending June 30,
2018, net sales increased 3.4% to $602.9 million, or $597.5 million with
the adoption of ASC 606. On a constant currency basis, net sales for the
first half of 2018 increased 1.1% over net sales in the first half of
2017. The number of selling days in the quarter was the same as in the
prior year period.

Net sales for DJO's Surgical Implant segment
grew 7.9% in the quarter to $53.9 million. The company's shoulder
implant product line was a key contributor with strong double-digit
growth compared to the same quarter in the prior year. For the six
months ending June 30, 2018, the Surgical Implant segment grew 8.0% over
the prior year period to $107.5 million.

Net sales for DJO's International segment
grew 9.3% in the second quarter to $87.0 million, or 3.5% on a constant
currency basis. The company's sales growth in Germany, France and
Australia were partially offset by market conditions in Canada and the
United Kingdom. For the six months ending June 30, 2018, the
International segment revenue was $175.6 million, an increase of 11.3%,
or 2.8% on a constant currency basis.

Net sales for DJO's Recovery Sciences segment
were $37.5 million in the second quarter, a year-over-year decrease of
3.4%. Strong growth in the segment's Regeneration CMF product line was
offset by softness in the Chattanooga product line compared to the prior
year period. For the six months ending June 30, 2018, the Recovery
Sciences segment declined 5.1% to $73.3 million.

Net sales for DJO's Bracing and Vascular segment
grew 4.4% to $131.9 million in the second quarter, or $126.5 with the
adoption of ASC 606. There was strong growth in the segment's DonJoy
product line, partially offset by weakness in the Dr. Comfort footwear
product line. Strong demand for new products, strength in acute care and
continued progress in transformation initiatives to improve service
levels contributed to the results. For the six months ending June 30,
2018, Bracing and Vascular net sales were $246.4 million, a decline of
0.8% from the first half of 2017, or $241.0 million with the adoption of
ASC 606.

Earnings Results

Operating income was $35.8 million in the
quarter, an increase of 296% over the prior year period. For the six
months ending June 30, 2018, operating income was $69.3 million, an
increase of 341% over the prior year. Net loss attributable to DJOFL was
$13.7 million in the quarter compared to $34.4 million in the prior year
period. For the six months ended June 30, net loss was $31.3 million
compared to $74.4 million in the six month ended July 1, 2017.

Adjusted EBITDA for the second quarter was
$75.6 million, an increase of 19.0% from the prior year period, or 17.0%
on the basis of constant currency. For the six months ended June 30,
2018, Adjusted EBITDA was $140.4 million, up 16.2% from the prior year,
or 14.5% on a constant currency basis. Including projected future
run-rate savings of $24.8 million from cost savings programs currently
underway as permitted under our credit agreement and the indentures
governing our outstanding notes, Adjusted EBITDA for the twelve months
ended June 30, 2018 was $312.6 million.

Net cash provided by continuing operating
activities
was $9.0 million for the six months ended June 30,
2018 compared to $38.1 million for the six months ended July 1, 2017.
The change in cash flow was primarily attributable to higher inventory
balances to allow for the modernization and consolidation of
distribution facilities as part of the Company's transformation
initiatives, and to the payment in 2018 of certain non-recurring costs
accrued in 2017.

The Company defines Adjusted EBITDA as net (loss) income attributable to
DJOFL plus net interest expense, income tax provision (benefit), and
depreciation and amortization, further adjusted for certain non-cash
items, non-recurring items and other adjustment items as permitted in
calculating covenant compliance under the Company's secured term loan
and revolving credit facilities ("Senior Secured Credit Facilities") and
the indentures governing its 8.125% second lien notes and its 10.75%
third lien notes. A reconciliation between net loss attributable to
DJOFL and Adjusted EBITDA is included in the attached financial tables.

Conference Call Information

DJO has scheduled a conference call to discuss this announcement
beginning at 4:30 pm, Eastern Time Monday, August 6, 2018. Individuals
interested in listening to the conference call may do so by dialing
(866) 394-8509 (International callers please use (346) 265-0698), using
the reservation code 22322226. A telephone replay will be available for
48 hours following the conclusion of the call by dialing (855) 859-2056
and using the above reservation code. The live conference call and
replay will be available via the Internet at www.DJOglobal.com.

About DJO Global

DJO Global is a leading global provider of medical technologies designed
to get and keep people moving. The Company's products address the
continuum of patient care from injury prevention to rehabilitation,
enabling people to regain or maintain their natural motion. Its products
are used by orthopaedic surgeons, primary care physicians, pain
management specialists, physical therapists, podiatrists, chiropractors,
athletic trainers and other healthcare professionals. In addition, many
of the Company's medical devices and related accessories are used by
athletes and patients for injury prevention and at-home physical therapy
treatment. The Company's product lines include rigid and soft
orthopaedic bracing, hot and cold therapy, bone growth stimulators,
vascular therapy systems and compression garments, therapeutic shoes and
inserts, electrical stimulators used for pain management and physical
therapy products. The Company's surgical division offers a comprehensive
suite of reconstructive joint products for the hip, knee and shoulder.
DJO Global's products are marketed under a portfolio of brands including
Aircast®, Chattanooga, CMF™, Compex®, DonJoy®, ProCare®, DJO® Surgical,
Dr. Comfort® and ExosTM. For additional information on the
Company, please visit www.DJOglobal.com.

Safe Harbor Statement

This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended. Such
statements relate to, among other things, the Company's expectations for
improved liquidity, estimated cost reductions associated with the
execution of its business transformation plans and improved
efficiencies. The words "believe," "will," "should," "expect," "target,"
"intend," "estimate" and "anticipate," variations of such words and
similar expressions identify forward-looking statements, but their
absence does not mean that a statement is not a forward-looking
statement. These forward-looking statements are based on the Company's
current expectations and are subject to a number of risks, uncertainties
and assumptions, many of which are beyond the Company's ability to
control or predict. The Company undertakes no obligation to update any
forward-looking statements, whether as a result of new information,
future events or otherwise. The important factors that could cause
actual operating results to differ significantly from those expressed or
implied by such forward-looking statements include, but are not limited
to the successful execution of the Company's business transformation
plans, including achievement of planned actions to improve liquidity,
improvements in operational effectiveness, optimization of the Company's
procurement activities, improvements in manufacturing, distribution,
sales and operations planning, and actions to improve the profitability
of the mix of our product and customers. Other important factors that
could cause actual operating results to differ significantly from those
expressed or implied by such forward-looking statements include, but are
not limited to: business strategies relative to our Bracing and
Vascular, Recovery Sciences, International and Surgical Implant
segments; the continued growth of the markets the Company addresses and
any impact on these markets from changes in global economic conditions;
the impact of potential reductions in reimbursement levels and coverage
by Medicare and other governmental and commercial payers; the Company's
highly leveraged financial position; the Company's ability to
successfully develop, license or acquire, and timely introduce and
market new products or product enhancements; risks relating to the
Company's international operations; resources needed and risks involved
in complying with government regulations and government investigations;
the availability and sufficiency of insurance coverage for pending and
future product liability claims; and the effects of healthcare reform,
Medicare competitive bidding, managed care and buying groups on the
prices of the Company's products. These and other risk factors related
to DJO are detailed in the Company's Annual Report on Form 10-K for the
year ended December 31, 2017, filed with the Securities and Exchange
Commission on March 16, 2018. Many of the factors that will determine
the outcome of the subject matter of this press release are beyond the
Company's ability to control or predict.

   
DJO FINANCE LLC
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands)
 
Three Months Ended Six Months Ended

June 30,
2018

 

July 1,
2017

June 30,
2018

 

July 1,
2017

Net sales $ 304,837 $ 294,746 $ 597,466 $ 583,135
Operating expenses:
Cost of sales (exclusive of amortization of intangible assets of
$6,635 and $13,293 for the three and six months ended June 30, 2018,
respectively and $6,980 and $13,961 for the three and six months
ended July 1, 2017, respectively)
126,443 124,885 246,379 244,454
Selling, general and administrative 117,626 135,739 232,942 269,901
Research and development 9,707 9,063 18,988 18,202
Amortization of intangible assets   15,289   16,016   29,888   34,861
  269,065   285,703   528,197   567,418
Operating income 35,772 9,043 69,269 15,717
Other (expense) income:
Interest expense, net (45,779 ) (43,068 ) (89,701 ) (85,755 )
Other (expense) income, net   1,054   896   (487 )   1,184
  (44,725 )   (42,172 )   (90,188 )   (84,571 )
Loss before income taxes (8,953 ) (33,129 ) (20,919 ) (68,854 )
Income tax provision   4,635   1,095   10,019   5,173
Net loss from continuing operations (13,588 ) (34,224 ) (30,938 ) (74,027 )
Net income from discontinued operations   178   47   321   105
Net loss (13,410 ) (34,177 ) (30,617 ) (73,922 )
Net income attributable to noncontrolling interests   (276 )   (206 )   (638 )   (430 )
Net loss attributable to DJO Finance LLC $ (13,686 ) $ (34,383 ) $ (31,255 ) $ (74,352 )
 
             

DJO FINANCE LLC

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)

 

June 30,
2018

December 31,
2017

ASSETS
Current assets:
Cash and cash equivalents $ 26,789 $ 31,985
Accounts receivable, net 179,611 190,324
Inventories, net 177,273 169,137
Prepaid expenses and other current assets 32,144 20,218
Current assets of discontinued operations   511   511
Total current assets 416,328 412,175
Property and equipment, net 137,496 133,522
Goodwill 878,963 864,112
Intangible assets, net 585,268 607,088
Other assets   5,242   5,128
Total assets $ 2,023,297 $ 2,022,025
LIABILITIES AND DEFICIT
Current liabilities:
Accounts payable $ 105,144 $ 98,331
Accrued interest 18,615 18,015
Current portion of debt obligations 26,022 15,936
Other current liabilities   116,071   126,360
Total current liabilities 265,852 258,642
Long-term debt obligations 2,414,519 2,398,184
Deferred tax liabilities, net 146,108 142,597
Other long-term liabilities   20,968   13,080
Total liabilities $ 2,847,447 $ 2,812,503
Commitments and contingencies (Note 14)
Deficit:
DJO Finance LLC membership deficit:
Member capital 845,708 844,115
Accumulated deficit (1,646,850 ) (1,615,536 )
Accumulated other comprehensive loss   (25,579 )   (21,072 )
Total membership deficit (826,721 ) (792,493 )
Noncontrolling interests   2,571   2,015
Total deficit   (824,150 )   (790,478 )
Total liabilities and deficit $ 2,023,297 $ 2,022,025
 
 

See accompanying Notes to Unaudited Condensed Consolidated
Financial Statements.

 
           

DJO FINANCE LLC

UNAUDITED SEGMENT INFORMATION

(in thousands)

 
Three Months Ended Six Months Ended

June 30,
2018

     

July 1,
2017

June 30,
2018

     

July 1,
2017

Net sales:
Bracing and Vascular $ 126,512 $ 126,415 $ 241,001 $ 248,468
Recovery Sciences 37,454 38,774 73,347 77,277
Surgical Implant 53,918 49,991 107,537 99,583
International   86,953   79,566   175,581   157,807
$ 304,837 $ 294,746 $ 597,466 $ 583,135
Operating income:
Bracing and Vascular $ 29,257 $ 24,225 $ 49,255 $ 45,232
Recovery Sciences 9,656 10,709 18,249 19,616
Surgical Implant 11,166 10,062 22,930 18,202
International 19,436 13,509 38,849 27,119
Expenses not allocated to segments and eliminations   (33,743 )   (49,462 )   (60,014 )   (94,452 )
$ 35,772 $ 9,043 $ 69,269 $ 15,717
 

DJO Finance LLC
Adjusted EBITDA

For the Six Months Ended June 30, 2018 and July 1, 2017
(unaudited)

Our Senior Secured Credit Facilities, consisting of a $1,055.0 million
term loan facility (including a $20.0 million delayed draw term loan
facility) and a $150.0 million asset-based revolving credit facility,
under which $87.5 million was outstanding as of June 30, 2018, and the
Indentures governing our $1,015.0 million of 8.125% second lien notes
and $298.5 million of 10.75% third lien notes (collectively, the
"notes") represent significant components of our capital structure.
Under our Senior Secured Credit Facilities, we are required to maintain
a specified senior secured first lien leverage ratio, which is
determined based on our Adjusted EBITDA. If we fail to comply with the
senior secured first lien leverage ratio under our Senior Secured Credit
Facilities, we would be in default. Upon the occurrence of an event of
default under the Senior Secured Credit Facilities, the lenders could
elect to declare all amounts outstanding under the Senior Secured Credit
Facilities to be immediately due and payable and terminate all
commitments to extend further credit. If we were unable to repay those
amounts, the lenders under the Senior Secured Credit Facilities could
proceed against the collateral granted to them to secure that
indebtedness. We have pledged substantially all of our assets as
collateral under the Senior Secured Credit Facilities and under the
notes. Any acceleration under the Senior Secured Credit Facilities would
also result in a default under the Indentures governing the notes, which
could lead to the note holders electing to declare the principal,
premium, if any, and interest on the then outstanding notes immediately
due and payable. In addition, under the Indentures governing the notes,
our and our subsidiaries' ability to engage in activities such as
incurring additional indebtedness, making investments, refinancing
subordinated indebtedness, paying dividends and entering into certain
merger transactions is governed, in part, by our ability to satisfy
tests based on Adjusted EBITDA. Our ability to meet the covenants
specified in the Senior Secured Credit Facilities and the Indentures
governing those notes will depend on future events, some of which are
beyond our control, and we cannot assure you that we will meet those
covenants.

Adjusted EBITDA is defined as net income (loss) attributable to DJOFL
plus interest expense, net, income tax provision (benefit), and
depreciation and amortization, further adjusted for certain non-cash
items, non-recurring items and other adjustment items as permitted in
calculating covenant compliance and other ratios under our Senior
Secured Credit Facilities and the Indentures governing the notes. We
believe that the presentation of Adjusted EBITDA is appropriate to
provide additional information to investors about the calculation of,
and compliance with, certain financial covenants and other ratios in our
Senior Secured Credit Facilities and the Indentures governing the notes.
Adjusted EBITDA is a material component of these calculations.

Adjusted EBITDA should not be considered as an alternative to net income
(loss) attributable to DJOFL or other performance measures presented in
accordance with accounting principles generally accepted in the United
States of America ("GAAP"), or as an alternative to cash flow from
operations as a measure of our liquidity. Adjusted EBITDA does not
represent net income (loss) attributable to DJOFL or cash flow from
operations as those terms are defined by GAAP and does not necessarily
indicate whether cash flows will be sufficient to fund cash needs. In
particular, the definition of Adjusted EBITDA under our Senior Secured
Credit Facilities and the Indentures governing the notes allows us to
add back certain non-cash, extraordinary, unusual or non-recurring
charges that are deducted in calculating net income (loss) attributable
to DJOFL. However, these are expenses that may recur, vary greatly and
are difficult to predict. While Adjusted EBITDA and similar measures are
frequently used as measures of operations and the ability to meet debt
service requirements, Adjusted EBITDA is not necessarily comparable to
other similarly titled captions of other companies due to the potential
inconsistencies in the method of calculation.

The following table provides reconciliation between net income (loss)
attributable to DJOFL and Adjusted EBITDA (in thousands):

                                     
Twelve
Months
Three Months Ended Six Months Ended Ended
June 30, July 1, June 30, July 1, June 30,
2018 2017 2018 2017 2018
Net loss attributable to DJO Finance LLC $ (13,686 ) $ (34,383 ) $ (31,255 ) $ (74,352 ) $ 7,203
Income loss from discontinued operations, net (178 ) (47 ) (321 ) (105 ) (525 )
Interest expense, net 45,779 43,068 89,701 85,755 178,184
Income tax provision (benefit) 4,635 1,095 10,019 5,173 (55,873 )
Depreciation and amortization 27,871 26,942 53,376 56,716 107,921
Non-cash charges (a) 524 537 749 1,108 4,742
Non-recurring and integration charges (b) 10,737 25,195 16,257 43,584 41,922
Other adjustment items (c)   (68 )   1,142   1,888   2,911   4,242
75,614 63,549 140,414 120,790 287,816
Permitted pro forma adjustments applicable to the twelve-month
period only – Note 1
 
Future cost savings                   24,810
Adjusted EBITDA $ 75,614 $ 63,549 $ 140,414 $ 120,790 $ 312,626

________________________________________

Note 1 — Permitted pro forma adjustments include future cost savings
from cost reduction actions related to our business transformation
initiative, recognized as permitted under our credit agreement and the
indentures governing our notes.

(a) Non-cash charges are comprised of the following (in thousands):

                                   
Twelve
Months
Three Months Ended Six Months Ended Ended
June 30, July 1, June 30, July 1, June 30,
2018 2017 2018 2017 2018
Stock compensation expense $ 447 $ 392 $ 895 $ 846 $ 3,745
(Gain) loss on disposal of fixed assets and assets held for sale, net   77   145   (146 )   262   997
Total non-cash charges $ 524 $ 537 $ 749 $ 1,108 $ 4,742
 

(b) Non-recurring and integration charges are comprised of the following
(in thousands):

                                 
Twelve
Months
Three Months Ended Six Months Ended Ended
June 30, July 1, June 30, July 1, June 30,
2018 2017 2018 2017 2018
Restructuring and reorganization (1) $ 7,823 $ 23,273 $ 11,492 $ 39,069 $ 32,665
Acquisition related expenses and integration (2) 379 277 749 579 2,276
Executive transition - (49 ) - (49 ) -
Litigation and regulatory costs and settlements, net 2,535 1,290 4,016 3,392 6,881
IT automation projects   -   404   -   593   100
Total non-recurring and integration charges $ 10,737 $ 25,195 $ 16,257 $ 43,584 $ 41,922
 

(1) Consist of costs related to the Company's business transformation
projects to improve the Company's operational profitability and
liquidity.
(2) Consists of direct acquisition costs and integration
expenses related to acquired businesses and costs related to potential
acquisitions.


(c) Other adjustment items before
permitted pro forma adjustments are comprised of the following (in
thousands):

                               
Twelve
Months
Three Months Ended Six Months Ended Ended
June 30, July 1, June 30, July 1, June 30,
2018 2017 2018 2017 2018
Blackstone monitoring fees $ - $ 1,750 $ - $ 3,500 $ 2,725
Non-controlling interests 276 206 638 430 1,007
Foreign currency transaction losses (gains) and other expense
(income)
(1,054 ) - 487 - (444 )
Franchise and other tax 710 - 763 - 954
Other (1)   -   (814 )   -   (1,019 )   -
Total other adjustment items $ (68 ) $ 1,142 $ 1,888 $ 2,911 $ 4,242
 

(1) Other adjustments consist primarily of net realized and unrealized
foreign currency translation gains and losses.

View Comments and Join the Discussion!